Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
In unselected patients with advanced BTC, adding bevacizumab to atezolizumab plus CisGem modestly improves PFS but not OS. High <i>VEGFA</i> gene expression may represent a predictive biomarker of benefit from atezolizumab/bevacizumab, warranting further investigation.
Authors
- Tiziana Pressiani (ORCID: https://orcid.org/0000-0001-6919-1536)
- Anthony B. El-Khoueiry (ORCID: https://orcid.org/0000-0002-9053-3841)
- Stephanie Wu (ORCID: https://orcid.org/0009-0002-1477-8991)
- Andrew X. Zhu (ORCID: https://orcid.org/0000-0001-7495-1528)
- Daneng Li (ORCID: https://orcid.org/0000-0001-5330-7522)
- Joon Oh Park (ORCID: https://orcid.org/0000-0001-6502-2612)
- Stephen P. Hack (ORCID: https://orcid.org/0000-0002-0640-5709)
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Lyudmila Zhukova (ORCID: https://orcid.org/0000-0003-4848-6938)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Xiangnan Guan
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
- Yulei Wang (ORCID: https://orcid.org/0000-0002-9057-9786)
- Jin Won Kim (ORCID: https://orcid.org/0000-0002-1357-7015)
- Shan Lu
- Zhenggang Ren (ORCID: https://orcid.org/0000-0002-2799-547X)
- Bo Liu (ORCID: https://orcid.org/0009-0005-6182-8172)
Institutions
- City Of Hope National Medical Center (US)
- Fudan University (CN)
- Samsung Medical Center (KR)
- Taipei Veterans General Hospital (TW)
- Seoul National University Bundang Hospital (KR)
- Moscow Clinical Scientific Center (RU)
- City of Hope (US)
- USC Norris Comprehensive Cancer Center (US)
- Zhongshan Hospital (CN)
- Vall d'Hebron Hospital Universitari (ES)
- CHA University Bundang Medical Center (KR)
- IRCCS Humanitas Research Hospital (IT)
- Vall d'Hebron Institute of Oncology (ES)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1200/jco.24.00337
- Citations
- 26
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 14.89
Funders
- F. Hoffmann-La Roche
- Genentech